Browse > Article

A Systematic Review on Drug Safety for Molsidomine, Nicorandil and Trimetazidine  

Jeong, Kyeong Hye (College of Pharmacy, Chung-Ang University)
Lee, Euni (College of Pharmacy, Seoul National University)
Publication Information
Korean Journal of Clinical Pharmacy / v.26, no.2, 2016 , pp. 172-180 More about this Journal
Abstract
Background: Ischemic heart disease is the most common type of heart disease and an important cause of death in Korea. Among marketed anti-anginal medications, molsidomine, nicorandil, and trimetazidine are approved in Korea with unique mechanism of actions. As these drugs are not approved by the US Food and Drug Administration, the access to the up-to-dated and comprehensive safety-related information has been less than optimal from drug information resources used by Korean pharmacists. Methods: A systematic review was conducted using Embase and Korean manuscripts to compile safety updates for these medications. Out of 418 articles from keyword searches, 52 studies were reviewed in full to compare adverse effects (AEs) with the approved package inserts (PI). Results: Molsidomine related adverse effects were mostly mild or moderate, but anxiety, palpitation, epigastric pain, and sexual potency reduction were additional AEs found from the review not listed in PI. Although PI has included ulceration in oral cavity and gastrointestinal tracts including anus by nicorandil, the Korea FDA recently recommended adding corneal, genital, and skin ulcers to the approved PI. Trimetazidine induced Parkinsonism, worsening of the symptoms for patients diagnosed with Parkinson's disease, gastrointestinal burning, and muscle cramps were additionally identified AEs not listed in PI for trimetazidine. Conclusion: Continuous evaluations of the safety profile of these agents are needed to balance the risks and benefits to provide evidence-based safety counseling to the patients. In addition, more focused efforts on spontaneous reporting are warranted by healthcare professionals to safeguard patients against AEs.
Keywords
Molsidomine; nicorandil; trimetazidine; safety; adverse effects;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Doring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: Results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 1992;20(suppl. 3):S74-81.
2 Raftery EB, Lahiri A, Hughes LO, et al. A double-blind comparison of a beta-blocker and a potassium channel opener in exercise induced angina. Eur Heart J 1993;14(suppl. B):35-9.   DOI
3 Markham A, Plosker GL, Goa KL. Nicorandil: An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs 2000;60(4):955-74.   DOI
4 Horinaka S. Use of nicorandil in cardiovascular disease and its optimization. Drugs 2011;71(9):1105-19.   DOI
5 Cross HR. Trimetazidine for stable angina pectoris. Expert Opin on Pharmacother 2001;2(5):857-75.   DOI
6 Chrusciel P, Rysz J, Banach M. Defining the role of trimetazidine in the treatment of cardiovascular disorders: Some insights on its role in heart failure and peripheral artery disease. Drugs 2014;74(9):971-80.   DOI
7 Roland E. Safety profile of an anti-anginal agent with potassium channel opening activity: An overview. Eur Heart J 1993;14(suppl. B):48-52.
8 Sasaki J, Saeki Y, Kawasaki K, et al. A multicenter comparison of nicorandil and diltiazem on serum lipid, apolipoprotein, and lipoprotein levels in patients with ischemic heart disease. Cardiovac Drugs Ther 1992;6(5):471-4.   DOI
9 Wagner G. Selected issues from an overview on nicorandil: Tolerance, duration of action, and long-term efficacy. J Cardiovasc Pharmacol 1992;20(suppl. 3):S86-92.   DOI
10 Krumenacker M, Roland E. Clinical profile of nicorandil: An overview of its hemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol 1992;20(suppl. 3):S93-102.
11 Dunn N, Freemantle S, Pearce G, et al. Safety profile of nicorandil - Prescription-event monitoring (PEM) study. Pharmacoepidemiol Drug Saf 1999;8(3):197-205.   DOI
12 Terai H, Yamanishi H, Shimahara M. Nicorandil-induced tongue ulceration with or without fungal infection. Odontology 2012;100(1):100-3.   DOI
13 Scully C, Azul AM, Crighton A, et al. Nicorandil can induce severe oral ulceration. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91(2):189-93.   DOI
14 Egred M. Nicorandil-associated ulcerations. Eur J Gastroenterol Hepatol 2007;19(5):395-8.   DOI
15 Salim F, Joshi A, Hopkins C. Ulceration of the nasal dorsum: a rare cause? J Laryngol Otology 2014;128(3):289-91.   DOI
16 Gayet JL, Paganelli F, Cohen-Solal A. Update on the medical treatment of stable angina. Arch Cardiovas Dis 2011;104(10):536-44.   DOI
17 Fraunfelder FW, Fraunfelder FT. Conjunctival and corneal ulceration associated with nicorandil. Cutan Ocul Toxicol 2014;33(2):120-1.   DOI
18 Trechot F, Batta B, Petitpain N, et al. A case of nicorandil-induced unilateral corneal ulceration. Int Wound J 2014;11(3):238-9.   DOI
19 Campolmi N, Guy C, Cinotti E, et al. Corneal perforation: Another side effect of nicorandil. Cutan Ocul Toxicol 2014;33(2):96-8.   DOI
20 Trechot P, Petitpain N, Guy C, et al. Nicorandil: From ulcer to fistula into adjacent organs. Int Wound J 2013;10(2):210-3.   DOI
21 Onay-Besikci A, Özkan SA. Trimetazidine revisited: A comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine. Cardiovas Ther 2008;26(2):147-65.   DOI
22 The Korean-English Medical Terminology, 5th Edition, Korean Medical Association. Available from http://term.kma.org/. Accessed April 14, 2016.
23 Lehmann G, Reiniger G, Beyerle A, et al. Clinical comparison of antiischemic efficacy of isosorbide dinitrate and molsidomine. J Cardiovasc Pharmacol 1998;31(1):25-30.   DOI
24 Lehmann G, Reiniger G, Beyerle A, et al. Haemodynamic evaluation of two regimens of molsidomine in patients with chronic congestive heart failure. Eur J Clin Pharmacol 1995;48(2):109-14.   DOI
25 Falase BA, Bajaj BS, Wall TJ, et al. Nicorandil-induced peripheral vasodilatation during cardiopulmonary bypass. Ann Thorac Surg 1999;67(4):1158-9.   DOI
26 Bricaud H, Brottier L, Barat JL, et al. Cardioprotective effect of trimetazidine in severe ischemic cardiomyopathy. Cardiovasc Drugs Ther 1990;4 Suppl 4:861-5.   DOI
27 Brottier L, Barat JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 1990;11(3):207-12.   DOI
28 Ruzyllo W, Szwed H, Sadowski Z, et al. Efficacy of trimetazidine in patients with recurrent angina: A subgroup analysis of the TRIMPOL II study. Curr Med Res Opin 2004;20(9):1447-54.   DOI
29 Bertel O, Noll G. Additional molsidomine in refractory unstable angina pectoris. Cardiovasc Drugs Ther 1988;2(1):107-11.   DOI
30 Makolkin VI, Osadchiy KK. Trimetazidine modified release in the treatment of stable angina: TRIUMPH Study. Clin Drug Investig 2004;24(12):731-8.   DOI
31 Palaniappan M, Selvarajan S, George M, et al. Pattern of adverse drug reactions reported with cardiovascular drugs in a tertiary care teaching hospital. J Clin Diagn Res 2015;9(11):FC01-4.
32 Toquero L, Briggs CD, Bassuini MM, et al. Anal ulceration associated with nicorandil: Case series and review of the literature. Colorectal Disease 2006;8(8):717-20.   DOI
33 Kapoor S. Nicorandil and its associated gastrointestinal side effects. Pacing Clin Electrophysiol 2013;36(5):662.   DOI
34 Baker RP, Al-Kubati W, Atuf M, et al. Nicorandil-induced severe perianal ulceration. Tech Coloproctol 2007;11(4):343-5.   DOI
35 Yap T, Philippou P, Perry M, et al. Nicorandil-induced penile ulcerations: A case series. BJU Int 2011;107(2):268-71.   DOI
36 McDaid J, Reichl C, Hamzah I, et al. Diverticular fistulation is associated with nicorandil usage. Ann R Coll Surg Engl 2010;92(6):463-5.   DOI
37 Kinoshita M, Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc Drugs Ther 1990;4(4):1075-88.   DOI
38 Balakumar P, Kavitha M, Nanditha S. Cardiovascular drugs-induced oral toxicities: A murky area to be revisited and illuminated. Pharmacol Res 2015;102:81-9.   DOI
39 Shapey IM, Agbamu D, Newall N, et al. Nicorandil-associated ulceration of the gastrointestinal tract: side effects requiring surgical intervention. Int J of Colorectal Dis 2015;30(8):1143-5.   DOI
40 Overview of Korean healthcare system based on the Korea Healthcare Panel (2008-2012). Available from https://www.khp.re.kr:444/ver_2/04_study/study01.jsp. Accessed March 25, 2016.
41 Vital Statistics in 2014 on Cause of Death. Available from http://kostat.go.kr/portal/korea/kor_nw/2/6/2/index.board?bmode=read&aSeq=348539. Accessed April 14, 2016.
42 The average life expectancy (0 years life expectancy) and healthy life. Available from http://www.index.go.kr/potal/main/EachDtlPageDetail.do?idx_cd=2758. Accessed March 25, 2016.
43 Mortality trends by cause of death. Available from http://www.index.go.kr/potal/main/EachDtlPageDetail.do?idx_cd=1012. Accessed March 25, 2016.
44 Reden J. Molsidomine. Blood Vessels 1990;27(2-5):282-94.
45 Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005;91(2):161-5.   DOI
46 Shlyakhto EV, Almazov VVA, Nifontov EM, et al. Antianginal effects of trimetazidine and left ventricular function improvement in patients with stable angina pectoris. Am J Cardiovasc Drugs 2002;2(2):119-24.   DOI
47 Dalla-Volta S, Maraglino G, Della-Valentina P, et al. Comparison of trimetazidine with nifedipine in effort angina: A double-blind, crossover study. Cardiovasc Drugs Ther 1990;4(suppl. 4):853-9.   DOI
48 McClellan KJ, Plosker GL. Trimetazidine: A review of its use in stable angina pectoris and other coronary conditions. Drugs 1999;58(1):143-57.   DOI
49 Marti Masso JF, Marti I, Carrera N, et al. Trimetazidine induces parkinsonism, gait disorders and tremor. Therapie 2005;60(4):419-22.   DOI
50 Marti Masso JF. Trimetazidine-induced parkinsonism. Neurologia 2004;19(7):392-5.
51 Masmoudi K, Masson H, Gras V, et al. Extrapyramidal adverse drug reactions associated with trimetazidine: A series of 21 cases. Fundam Clin Pharmacol 2012;26(2):198-203.   DOI
52 Messin R, Dubois C, Famaey JP. Comparative effects of once-daily molsidomine in coronary patients from two distinct European ethnicities. Adv Ther 2008;25(11):1200-14.   DOI
53 Messin R, Carreer-Bruhwyler F, Dubois C, et al. Efficacy and safety of once- and twice-daily formulations of molsidomine in patients with stable angina pectoris: Double-blind and open-label studies. Adv Ther 2006;23(1):107-30.   DOI
54 Beaufils P, Kolsky H, Haiat R, et al. The influence of molsidomine on infarct size: An acute post-infarction pilot study with 303 patients. Cardiovasc Drugs Ther 1988;2(1):127-32.   DOI
55 Balakumaran K, Hugenholtz PG, Tijssen JGP, et al. Molsidomine, an effective long-acting anti-anginal drug. Eur Heart J 1983;4(9):655-61.   DOI
56 Nishimura M, Tokoro T, Nishida M, et al. Oral Nicorandil to reduce cardiac death after coronary revascularization in hemodialysis patients: A randomized trial. Am J Kidney Dis 2009;54(2):307-17.   DOI
57 Blanc P, Aouifi A, Bouvier H, et al. Safety of oral nicorandil before coronary artery bypass graft surgery. Br J Anaesth 2001;87(6):848-54.   DOI
58 Wolf DL, Hearron AE, Metzler CM, et al. The pharmacokinetics and haemodynamic effects of continuous nicorandil infusion in healthy volunteers. Eur J Clin Pharmacol 1993;45(5):437-43.   DOI
59 Ulvenstam G, Diderholm E, Frithz G, et al. Antianginal and antiischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. J Cardiovasc Pharmacol 1992;20(suppl. 3):S67-73.   DOI